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DOI 10.1016/j.ccr.2011.07.016SUMMARYWe show constitutive activation of Rho kinase (ROCK) in cells bearing oncogenic forms of KIT, FLT3, and
BCR-ABL, which is dependent on PI3K and Rho GTPase. Genetic or pharmacologic inhibition of ROCK in
oncogene-bearing cells impaired their growth as well as the growth of acute myeloid leukemia patient-
derived blasts and prolonged the life span of mice bearing myeloproliferative disease. Downstream from
ROCK, rapid dephosphorylation or loss of expression of myosin light chain resulted in enhanced apoptosis,
reduced growth, and loss of actin polymerization in oncogene-bearing cells leading to significantly prolonged
life span of leukemic mice. In summary we describe a pathway involving PI3K/Rho/ROCK/MLC that may
contribute to myeloproliferative disease and/or acute myeloid leukemia in humans.INTRODUCTION
Although 70%–80% of patients with acute myeloid leukemia
(AML) go into remission with standard cytotoxic therapy, most
relapse and are unresponsive to subsequent therapies (Druker
et al., 2001a). Both AML and myeloproliferative disease (MPD)
increase in incidence dramatically in the aging population (Bau-
dard et al., 1994; Brincker, 1985). Unfortunately, elderly patients
fare worse than younger patients as a result of comorbidities
(Brincker, 1985). Therefore, it is important to develop therapies
with increased efficacy and reduced toxicity for these diseases.
The rational approach to less toxic and more efficacious ther-
apies for many hematologic malignancies is likely to involveSignificance
There are increasing examples of mutations in tyrosine kinase
myeloid leukemia (AML), and chronic myeloid leukemia (CML)
of systemic mastocytosis (SM), FLT3 internal tandem duplicati
tivation of several signaling molecules downstream from these
relative importance of downstream signaling molecules amon
KIT, FLT3, and BCR-ABL contribute to hematopoietic cell trans
ROCK is a potential therapeutic target for treating hematologi
Cantargeting molecules that are either mutated or hyperactivated
as a result of specific mutations. There are increasing examples
of mutations in signaling molecules including KIT mutations in
systemic mastocytosis (SM), gastrointestinal stromal tumors
(GISTs), and in core-binding factor AML (CBF-AML) (Beghini
et al., 2000; Hirota et al., 1998; Nagata et al., 1995), FLT3 internal
tandem duplications (FLT3-ITDs) in AML (Gilliland and Griffin,
2002; Nakao et al., 1996), and BCR-ABL translocations in
chronic myelogenous leukemia (CML) (Shtivelman et al., 1985).
Oncogenic KIT is constitutively phosphorylated, and when ex-
pressed in cell lines or primary bone marrow (BM), cells demon-
strate ligand-independent proliferation (Chian et al., 2001;
Kitayama et al., 1995; Piao and Bernstein, 1996). Although KITs that contribute to myeloproliferative disease (MPD), acute
including KIT mutations in AML as well as in over 90% cases
ons (ITDs) in AML, and BCR-ABL in CML. Although hyperac-
tyrosine kinases has been reported, little is known about the
g these mutations. We show here that activating mutants of
formation to a large extent via the hyperactivation of ROCK.
c malignancies involving these mutations.
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Figure 1. ROCK Activation Is Essential for Constitutive Growth of Oncogene-Bearing Cells
(A) Oncogene-bearing 32D cells were starved for 6 hr in serum- and cytokine-free medium and incubated in the presence or absence of H-1152 (2 mM) for 1 hr. An
equal amount of protein was subjected to western blot analysis using an anti-phospho-MYPT1 antibody. Similar results were observed in three independent
experiments.
(B) Cells in (A) were treated with indicated amounts of H-1152. After 48 hr, proliferation was evaluated by [3H]thymidine incorporation. Assay was performed in the
presence of IL-3 (10 ng/ml) for vector and WT receptor-bearing cells, and in the absence of IL-3 for oncogenic receptor-bearing cells. Bars denote the mean
thymidine incorporation ± SD from one of three independent experiments in quadruplicate (*p < 0.01).
(C) HSC/PCs bearing FLT3 or FLT3N51were treated with indicated amount of ROCK inhibitors. After 48 hr, proliferation was evaluated. Assays were performed in
the presence of IL-3 (10 ng/ml) for FLT3-bearing cells, and in the absence of IL-3 for FLT3N51-bearing cells. Bars denote the mean thymidine incorporation ± SD
from one of three independent experiments in quadruplicate (*p < 0.05).
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ROCK in Myeloproliferative Diseasemutations within the juxtamembrane region found in GIST are
sensitive to inhibition by imatinib mesylate (Gleevec), KIT muta-
tions within the tyrosine kinase domain, such as KITD816V, are
imatinib resistant (Demetri et al., 2002; Frost et al., 2002; Ma
et al., 2002).
Similar to the KIT, FLT3 is also a member of the class III
subfamily of receptor tyrosine kinase, and FLT3 mutations are
one of the most frequent somatic alterations in AML occurring
in approximately one-third of these patients and predict poor
prognosis (Fro¨hling et al., 2002; Gilliland and Griffin, 2002; Whit-
man et al., 2001). FLT3-ITD mutations also result in ligand-inde-
pendent constitutive activation of the receptor’s tyrosine kinase
activity (Kiyoi et al., 1998). Several FLT3 inhibitors have been
described, but they vary considerably with respect to selectivity
for FLT3 (Pratz et al., 2010). Similarly, nearly all patients with CML
express the BCR-ABL fusion protein, and stem cells bearing
BCR-ABL are sufficient to induceCML (Daley et al., 1990; Kosch-
mieder et al., 2005; Lugo et al., 1990; Shtivelman et al., 1985).
Although imatinib has been used successfully to treat CML,
emergence of BCR-ABL-positive residual stem cells and imati-
nib-resistant BCR-ABL mutants has resulted in drug resistance
and relapse-related concerns with this disease (Druker et al.,
2001a, 2001b; Graham et al., 2002). Thus, identification of new
targets, in particular that might contribute to the initiation and/
or progression of multiple hematologic malignancies involving
activated tyrosine kinases, is likely to be of therapeutic benefit.
Rho kinases (ROCKs) or Rho-associated coiled coil-contain-
ing protein kinases are protein serine/threonine kinases. Two
isoforms of ROCK have been described that are encoded by
two separate genes, ROCK1 and ROCK2 (Nakagawa et al.,
1996). ROCK1 and ROCK2 share considerable sequence
homology at the protein level: close to 65% overall and nearly
92% in their kinase domains (Nakagawa et al., 1996). Activation
of ROCK byGTP-bound Rho or by lipid mediators leads to phos-
phorylation of various downstream target proteins, including
myosin phosphatase (Kimura et al., 1996), myosin light chain
(MLC) (Leung et al., 1996), and LIM kinases 1 and 2 (Ohashi
et al., 2000; Sumi et al., 2001). Activation of these substrates
results in the recruitment of mediators of actin polymerization
and formation of focal adhesions leading to changes in growth,
survival, and cell motility (Riento and Ridley, 2003).
Emerging data suggest that ROCK is an oncogene. Recently,
cancer genome sequencing revealed three ROCK1-activating
mutations in primary human breast cancer cells and in human
nonsmall-cell lung carcinoma line NCI-H1770 (Greenman et al.,
2007). Introducing these mutants to fibroblasts elevated ROCK
activity, which lead to changes in actin cytoskeleton, increased
motility, and decreased adhesion (Lochhead et al., 2010). Taken
together, whereas a role for ROCK in solid tumors is clearly
emerging, its role in regulating growth, survival, and transforma-
tion downstream of tyrosine kinases involved in SM, AML, or
CML is not known. In the present study we determined the
contribution of PI3K/Rho/ROCK/MLC pathway in regulating the
growth, survival, and transformation of cells bearing oncogenic
forms of KIT, FLT3, and BCR-ABL.(D) Starved 32D cells bearing BCR-ABLT315I were cultured in the presence of indi
[3H]thymidine incorporation. Bars denote themean thymidine incorporation ± SD f
Figure S1.
CanRESULTS
Constitutive Activation of ROCK
in Oncogene-Bearing Cells
We first investigated the role of ROCK signaling in leukemogen-
esis mediated by activating mutant tyrosine kinases KITD814V,
FLT3N51, and BCR-ABL. 32D cells were starved, and ROCK
activity was analyzed by assessing the phosphorylation of its
substrate myosin phosphatase (MYPT1) in the presence or
absence of a highly specific and potent ROCK inhibitor H-1152
(Jacobs et al., 2006). Constitutive activation of ROCK was
observed only in oncogene-bearing cells, but not in cells bearing
the empty vector (MIEG3), KIT, or FLT3 (Figure 1A). Importantly,
H-1152 treatment rapidly inhibited the ROCK activity in onco-
gene-bearing cells (Figure 1A). Constitutive ROCK activity was
also observed in primary BM cells expressing KITD814V, but
not those expressing the wild-type (WT) KIT, and the activity
was completely inhibited by H-1152 (see Figure S1A available
online). Furthermore, H-1152 treatment has no effect on the acti-
vation of AKT, ERK, Stat5, and PKC in oncogene-bearing cells
(Figure S1). These results suggest that oncogenes such as
KITD814V, BCR-ABL, and FLT3N51 induce constitutive ROCK
activation, which is inhibited by H-1152.
ROCK Inhibitors Suppress the Constitutive Growth
of Oncogene-Bearing Cells
Next, we assessed whether ROCK inhibitors suppress the
growth of KITD814V, FLT3N51, and BCR-ABL-expressing cells.
32D cells bearing MIEG3 or KIT, or BaF3 cells bearing FLT3,
showed minimal thymidine incorporation in the absence of
growth factors. IL-3 enhances the growth of these cells. In
contrast, cells expressing KITD814V, BCR-ABL, or FLT3N51
showed constitutive growth in the absence of growth factors,
which was repressed by H-1152 in a dose-dependent manner.
Importantly, treatment of cells bearing MIEG3, KIT, or FLT3
with H-1152 in the presence of IL-3 showedminimal suppression
in proliferation (Figure 1B). Other ROCK inhibitors fasudil and
Y27632 similarly repress the growth of cells bearing KITD814V
or FLT3N51 (data not shown).
To validate whether the suppression in growth of oncogene-
bearing cells by ROCK inhibitors seen in 32D cells also occurs
in primary hematopoietic stem and progenitor cells (HSC/PCs),
we transduced primary HSC/PCs from C57BL/6 mice with
FLT3 or FLT3N51 and analyzed proliferation in the presence
or absence of ROCK inhibitors. Although primary HSC/PCs
bearing the FLT3 grown in the absence of growth factors
demonstrated minimal thymidine incorporation, cells bearing
the FLT3N51 demonstrated a significant increase in thymidine
incorporation in the absence of cytokine (Figure 1C). When stim-
ulated with IL-3, FLT3-bearing cells demonstrated a significant
increase in growth. When these cells were treated with
H-1152, a significant reduction in proliferation was observed in
cells bearing FLT3N51, but not those expressing FLT3. Consis-
tent with these results, treatment of these cells with less-potent
ROCK inhibitors fasudil and Y27632 also resulted in significantcated amounts of H-1152 or imatinib. After 48 hr, proliferation was evaluated by
romone of three independent experiments in quadruplicate (*p < 0.05). See also
cer Cell 20, 357–369, September 13, 2011 ª2011 Elsevier Inc. 359
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Figure 2. ROCK Inhibitor Suppresses the
Growth of Primary BM-Derived AML Blasts
(A) HMC1.2 or (B) MV4-11 cells were starved and
treated with indicated amounts of H-1152. After
48 hr, proliferation was evaluated. Bars denote the
mean thymidine incorporation ± SD from a repre-
sentative experiment performed in quadruplicate
(n = 3; *p < 0.001).
(C) AML patient sample was incubated in the
absence or presence of H-1152 (10 mM) for 1 hr,
and an equal amount of protein lysate was sub-
jected to western blot analysis using an anti-
phospho-MYPT1 antibody.
(D) Primary AML patient samples positive for FLT3-
ITD and mastocytosis patient samples positive for
KIT mutation were grown in the presence of indi-
cated cytokines including FLT3L (10 ng/ml), GM-
CSF (1 ng/ml), GM-CSF + IL-3 (1 + 10 ng/ml), GM-
CSF+FLT3L (1 + 50 ng/ml), or SCF (100 ng/ml) and
treated with indicated amounts of H-1152. After
48 hr, proliferation was evaluated. Bars denote the
mean thymidine incorporation ± SD performed in
triplicate or quadruplicate (*p < 0.01). See also
Figure S2 and Table S1.
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ROCK in Myeloproliferative Diseasereduction in the growth of cells expressing FLT3N51, but not
cells expressing FLT3 (Figure 1C). Similar repression in the
constitutive growth of primary HSC/PCs was observed in cells
bearing KITD814V and BCR-ABL in the presence of ROCK inhib-
itors (data not shown).
To determine whether the ROCK pathway is also involved in
the constitutive growth of cells bearing the imatinib-resistant
BCR-ABLT315I mutant, we treated 32D cells expressing this
mutant with H-1152. As expected, imatinib treatment showed
minimal effect on the growth of cells bearing BCR-ABLT315I.
In contrast, treatment of these same cells with H-1152 demon-
strated dose-dependent suppression in growth (Figure 1D).
These results suggest that ROCK may play a prominent role in
supporting the growth of oncogene-bearing cells, but only
a modest role in supporting the growth of nononcogene-bearing
hematopoietic cells.
ROCK Inhibitor Suppresses the Growth of Primary
BM-Derived Blasts from Patients with AML
We next performed studies in HMC1.2 cells bearing the acti-
vating KIT mutation (KITV560G and KITD816V) and in MV4-11360 Cancer Cell 20, 357–369, September 13, 2011 ª2011 Elsevier Inc.cells bearing the activating FLT3mutation
(FLT3-ITD) (Butterfield et al., 1988; Lange
et al., 1987). In both instances H-1152
showed a dose-dependent reduction in
growth of HMC1.2 and MV4-11 cells (Fig-
ures 2A and 2B). Likewise, cells derived
from patients with AML and mastocytosis
also demonstrated repression in ROCK
activity and growth in the presence of
H-1152 (Figures 2C, 2D, and S2, and
Table S1). Because we have not been
able to verify the status of KIT mutations
in all AML samples, it is conceivable thatthe growth of all AML cells to some extent is repressed by
ROCK inhibitors.
Rho GTPase Regulates ROCK
in Oncogene-Bearing Cells
We next determined the mechanism of activation of ROCK
in oncogene-bearing cells. We analyzed whether the small
Rho GTPase, which is upstream of ROCK, is involved in
KITD814V-induced growth and ROCK activation. C3 exoen-
zyme (a Rho inhibitor) inhibited the activation of ROCK and
the growth of cells bearing KITD814V or FLT3N51 (Figures
3A–3C). In addition cells coinfected with KITD814V and a domi-
nant-negative mutant of RhoA (RhoAN19) showed significantly
reduced growth compared to cells expressing KITD814V and
MIEG3 (Figure 3D). Consistent with in vitro findings, mice trans-
planted with cells bearing KITD814V and RhoAN19 showed
significantly prolonged survival compared to cells bearing
KITD814V and MIEG3 (Figure 3E). These results suggest that
RhoA is involved in KITD814V-induced constitutive growth
in vitro and MPD in vivo in part by regulating the activation
of ROCK.
A
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Figure 3. Rho GTPase Is Required for
Constitutive Growth and Activation of
ROCK in Oncogene-Bearing Cells
(A and B) KIT or KITD814V-expressing 32D cells
were treated with Rho inhibitor C3 exoenzyme
(5 mg/ml) for 2 hr and assessed for MYPT1 phos-
phorylation (A), or for 48 hr, and proliferation was
evaluated (B). Bars denote the mean thymidine
incorporation ± SD from one of three independent
experiments in quadruplicate (*p < 0.01).
(C) FLT3 or FLT3N51-expressing 32D cells were
treated with C3 exoenzyme (5 mg/ml). After 48 hr,
proliferation was evaluated. Bars denote the mean
thymidine incorporation ± SD from one of three
independent experiments in triplicate (*p < 0.01).
(D) Cells as in (B) were infected with a dominant-
negative mutant of RhoA (RhoAN19) and sub-
jected to proliferation assay. Bars denote the
mean thymidine incorporation ± SD from one of
three independent experiments in quadruplicate
(*p < 0.001).
(E) Kaplan-Meier survival curves of mice trans-
planted with cells coinfected with KITD814V and
MIEG3 or RhoAN19. A total of 1 3 106 cells were
injected into mice and monitored for MPD and
survival (n = 8 in each group; *p < 0.01).
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in Cells Bearing KITD814V
PI3K-mediated generation of PIP3 activates Rho GTPases by
regulating guanine exchange factors (Han et al., 1998; Schuebel
et al., 1998). PI3K plays an important role in KITD814V-induced
constitutive growth in vitro and MPD in vivo (Munugalavadla
et al., 2007, 2008). We determined if PI3K-induced MPD of
KITD814V-bearing cells involves ROCK. After starved of serum
and cytokine for 6 hr, PI3K and ROCK activities were observed
only in KITD814V-bearing cells, but not in KIT-expressing cells
(Figure 4A). Treatment of these cells with H-1152 for 1 hr com-
pletely inhibited the activation of ROCK but had no effect on
the activation of AKT. In contrast, 1 hr treatment with PI3K inhib-
itor LY294002 completely inhibited the activity of AKT and sig-
nificantly reduced the activity of ROCK in KITD814V-bearing
cells. These results suggest that PI3K is important for the activa-
tion of ROCK downstream from KITD814V.
To further analyze the role of PI3K in ROCK activation, primary
BM cells from WT and p85a/ mice transduced with KIT or
KITD814V were starved for 6 hr in serum- and cytokine-freeCancer Cell 20, 357–369, Semedium, and the activity of AKT and of
ROCK was measured. Constitutive acti-
vation of PI3K and ROCK was observed
in WT cells transduced with KITD814V,
but not KIT (Figure 4B). Importantly, dele-
tion of p85a resulted in significant inhibi-
tion of both AKT and ROCK activity in
KITD814V-bearing cells. These results
further support the notion that PI3K is
required for the activation of ROCK in
KITD814V-bearing cells.
To further study the contribution of
p85a in ROCK-induced MPD, we gener-
ated a chimeric KIT receptor (CHRKIT)and three derivatives (CHRD814V, CHRD814V-F7, and
CHRD814V-Y719). CHRD814V is corresponding to KITD814V.
CHRD814V-F7 has all seven tyrosine residues corresponding
to those in KITD814V known to bind SH2-containing proteins
(tyrosines 567, 569, 702, 719, 728, 745, and 934) mutated to
phenylalanine. CHRD814V-Y719 is similar to CHRD814V-F7
except that tyrosine residue 719 (the binding site for p85a) is
preserved. Loss of all tyrosine residues in KITD814V resulted in
complete loss of its ability to activate PI3K andROCK (Figure 4C).
Restoration of the p85a-binding site alone in KITD814V was
sufficient to completely restore the activation of both AKT and
ROCK. Furthermore, cells bearing CHRD814V or CHRD814V-
Y719 showed a similar level of ligand-independent growth,
compared to cells expressing CHRKIT or CHRD814V-F7 (Fig-
ure 4D; data not shown). Treatment of cells bearing CHRD814V
or CHRD814V-Y719 with H-1152 demonstrated a dose-depen-
dent inhibition in constitutive growth (Figure 4D). In contrast
lack of all tyrosine residues in KITD814V, which cannot activate
PI3K or ROCK, results in complete suppression of ligand-
independent growth. Consistent with cells bearing CHRKIT,ptember 13, 2011 ª2011 Elsevier Inc. 361
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Figure 4. PI3K Signaling Is Essential for
Constitutive Activation of ROCK in Cells
Bearing KITD814V
(A) 32D cells bearing KIT or KITD814V starved for
6 hr in serum- and cytokine-free medium were
treated as indicated (H-1152, 2 mM; LY294002,
2 mM) for 1 hr and subjected to western blot ana-
lysis. Similar results were observed in two inde-
pendent experiments.
(B) Starved primary WT or p85a/ HSC/PCs ex-
pressing KIT or KITD814V were subjected to
western blot analysis. Similar results were ob-
served in two independent experiments.
(C) Starved 32D cells bearing CHRKIT,
CHRD814V, CHRD814V-F7, or CHRD814V-Y719
were subjected to western blot analysis. Similar
results were observed in four independent exper-
iments.
(D) 32D cells bearing CHRD814V and CHRD814V-
Y719 were treated with indicated amounts of
H-1152 for 48 hr. After 48 hr, proliferation was
evaluated. Bars denote the mean thymidine
incorporation ± SD from one of four independent
experiments in quadruplicate (*p < 0.01).
(E) Kaplan-Meier survival curves of mice tran-
splanted with 32D cells bearing CHRKIT,
CHRD814V, CHRD814V-F7, or CHRD814V-Y719.
CHRD814V-F7 versus CHRD814V or CHRD814V-
Y719 (*p < 0.01; n = 8 mice in each group).
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ROCK in Myeloproliferative DiseaseH-1152 treatment showed only a moderate suppression in
growth of cells bearing CHRD814V-F7 in the presence of IL-3
(data not shown). Consistent with in vitro findings, mice trans-
planted with cells bearing CHRD814V or CHRD814-Y719 suc-
cumbed to MPD and died relatively early (within 3 ½weeks) after
transplantation (Figure 4E). In contrast, mice transplanted with
cells bearing CHRD814V-F7 survived for a significantly longer
time, and most mice died after 6–7 weeks of transplantation.
These results demonstrate that p85a-mediated activation of
PI3K is vital for constitutive activation of ROCK and growth of
KITD814V-bearing cells in vitro and transformation in vivo.
ROCK Inhibitor Prolongs the Survival of Leukemic Mice
and Modulates MPD In Vivo
We next assessed the in vivo impact of ROCK inhibitor treat-
ment on KITD814V-induced MPD. Mice transplanted with cells
bearing KITD814V were treated with phosphate-buffered saline
(PBS) or H-1152 at 24 hr intervals via oral gavage for 21 days
and monitored for MPD and survival. Although mice treated
with PBS died within 21 days of transplantation, mice treated
with H-1152 showed significantly prolonged survival (Figure 5A).
Mice treated with H-1152 showed significantly reduced spleen362 Cancer Cell 20, 357–369, September 13, 2011 ª2011 Elsevier Inc.and liver weight compared to PBS-
treated mice (Figures 5B and 5C). Similar
results were observed in an independent
experiment (Figure S3).
To further determine the efficacy of
ROCK inhibitors in treating MPD due to
activating mutations in receptor tyrosine
kinases, we performed similar pharmaco-
logical studies using a different oncogeneand a distinct ROCK inhibitor. We transplanted 32D cells bearing
FLT3N51 into syngenic C3H/HeJ mice through tail vein. After
2 weeks of transplantation, mice were treated with PBS (vehicle),
H-1152, or fasudil for 21 days and monitored for MPD and
survival. Although mice treated with PBS died within 34 days
of transplantation, treatment with H-1152 significantly prolonged
the survival of mice (Figure 5D). Treatment with fasudil also
showed similar efficacy in enhancing the survival of mice bearing
FLT3N51 (Figure 5D). After 5 weeks of prolonged survival com-
pared to PBS-treated mice, H-1152 or fasudil-treated mice
were sacrificed, and further analysis was performed. Mice
treated with H-1152 or fasudil showed significantly reduced
spleen and liver weights compared to PBS-treated mice (Figures
5E and 5F).
To further evaluate the antileukemic activity of ROCK inhibi-
tors, additional studies were performed using primary HSC/
PCs bearing KITD814V. After 10 days of transplantation, mice
were treated with PBS, H-1152, or fasudil for 21 days and moni-
tored for MPD and survival. Although PBS-treated mice died
within 24 days of transplantation, mice treated with H-1152 or
fasudil survived significantly longer (Figures 6A and 6B). Only
two out of five mice treated with either H-1152 or fasudil died
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Figure 5. In Vivo ROCK Inhibitor Treatment
of Oncogene-Bearing Mice Enhances Their
Survival and Modulates MPD
(A) Kaplan-Meier curves of mice transplanted with
1 3 106 32D cells bearing KITD814V through tail
vein and treated with PBS (n = 4) or H-1152 (n = 4)
at 24 hr intervals via oral gavage for 21 days
(*p < 0.01).
(B and C) Reduced splenomegaly and hepato-
megaly in mice treated with H-1152. Mean ± SEM
(n = 3; *p < 0.01).
(D) Kaplan-Meier curves of mice transplanted with
1 3 106 32D cells bearing FLT3N51 through tail
vein and treated with PBS (n = 5), H-1152 (n = 5,
oral gavage), or fasudil (n = 5, intraperitoneal) at
24 hr intervals for 21 days (*p < 0.01).
(E and F) Reduced splenomegaly and hepato-
megaly in mice treated with H-1152 or fasudil.
Spleen and liver were harvested from transplanted
mice treated with PBS (at moribund) or H-1152 or
fasudil (after 5 weeks of prolonged survival), and
weights were measured. Mean ± SD (n = 4–5;
*p < 0.01). See also Figure S3.
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ROCK in Myeloproliferative Diseasewithin 37 days of transplantation, and the remaining three
surviving mice were harvested at day 49 post-transplant for
further analysis. Consistent with the studies with 32D cells, treat-
ment with H-1152 or fasudil significantly modulates the patho-
logical features associated with MPD, such as increased white
blood cell and lymphocyte counts as well as splenomegaly and
hepatomegaly (Figures 6C–6F). These results suggest that
ROCK inhibitors significantly modulate MPD development in
mice transplanted with KITD814V or FLT3N51-bearing cells
and prolong the survival of these mice.
Deficiency of ROCK1 Suppresses the Growth
of KITD814V-Bearing Cells
To validate the pharmacologic findings usingH-1152 genetically,
we transduced primary HSC/PCs from WT and Rock1/ mice
with KIT or KITD814V and analyzed proliferation. Figure 7A
shows deletion of ROCK1 in Rock1/ HSC/PCs. As expected,
WT cells transduced with KITD814V, but not KIT, showed consti-
tutive growth in the absence of growth factors (Figure 7B). We
also observed hyperproliferation of WT cells transduced with
KITD814V compared to KIT in the presence of IL-3, SCF, and
G-CSF. In contrast, deficiency of ROCK1 resulted in correction
in the growth of cells bearing KITD814V compared to WT cells
in the presence or absence of IL-3, SCF, and G-CSF. In addition
treatment of Rock1/ cells bearing KITD814V with H-1152
showed no significant suppression in growth (Figure S4A). TheseCancer Cell 20, 357–369, Seresults suggest that ROCK1 is likely to
function as the predominant isoform of
ROCK in regulating KITD814V-induced
growth and MPD.
To further determine the contribution
of ROCK1 in KITD814V-induced MPD
in vivo, we transduced primary HSC/
PCs from 5-FU-treated WT or Rock1/
mice with KITD814V and transplanted
them into recipient mice and monitoredthem for MPD and survival. Although all recipient mice trans-
planted with WT cells bearing KITD814V died within 42 days of
transplantation, all recipient mice transplanted with Rock1/
cells bearing KITD814V survived for the entire duration of the
experiment (Figure 7C). Sixty-three days after transplantation,
mice expressing KITD814V in Rock1/ BM were harvested for
further analysis. Mice transplanted with Rock1/ cells bearing
KITD814V showed reduced spleen and liver weights as well
as white blood cell counts compared to mice transplanted
with WT cells bearing KITD814V (Figures 7D–7F; data not
shown). Furthermore, mice bearing an activating version of
ROCK1 also resulted in MPD and hypersensitivity to cytokines
(Figure S4).
ROCK Inhibitors Induce Cell Death
in Oncogene-Bearing Cells
To understand how ROCK inhibitors might inhibit the growth of
oncogene-bearing cells, we evaluated the survival of onco-
gene-bearing cells in the presence or absence of ROCK inhibi-
tors. Although H-1152 treatment induced only 5%–10% cell
death in KIT or MIEG3-bearing 32D cells, treatment of 32D cells
bearing the KITD814V or BCR-ABL with H-1152 resulted in
significantly greater and a dose-dependent increase in cell death
(Figures S5A andS5B). Similar results were observed using BaF3
cells bearing FLT3N51 and Y27632 (Figure S5C). These results
suggest that the reduced growth observed in cells bearing theptember 13, 2011 ª2011 Elsevier Inc. 363
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Figure 6. ROCK Inhibitor Enhances Survival
and Modulates MPD of Mice Transplanted
with KITD814V-Bearing Cells
(A and B) Kaplan-Meier curves of mice trans-
planted with primary HSC/PCs bearing KITD814V
(1 3 106) through tail vein and treated with PBS or
H-1152 or fasudil. After 10 days of transplantation,
mice were treated with PBS (n = 5) or H-1152 (n =
5, oral gavage) or fasudil (n = 5, intraperitoneal) at
24 hr interval for 21 days (*p < 0.05).
(C) Reduced white blood cell (WBC) and lympho-
cyte counts in mice treated with H-1152 or fasudil.
Mean ± SD (*p < 0.05).
(D and E) Reduced splenomegaly and hepato-
megaly in mice treated with H-1152 or fasudil.
Mean ± SD (*p < 0.01).
(F) Splenocytes from three mice transplanted with
KITD814V-bearing cells treated with PBS or
H-1152were lysed, and an equal amount of protein
lysates was subjected to western blot analysis
using indicated antibodies.
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ROCK in Myeloproliferative Diseaseoncogenes treated with ROCK inhibitors is in part due to
enhanced cell death. Furthermore, ROCK inhibitors are more
selective inducers of cell death in oncogene-bearing cells rela-
tive to WT receptor-bearing cells.
To determine the mechanism(s) by which suppression of
ROCK activity induces cell death in oncogene-bearing cells,
we investigated the activation of ERK, AKT, Stat5, PKA, and
PKC in H-1152-treated cells. Activation of all of these molecules
in oncogene-bearing cells was relatively unperturbed in the pres-
ence of H-1152 (Figures 4A and S1; data not shown). Although
cells bearing KIT, MIEG3, or FLT3 did not show constitutive
phosphorylation ofMLC, in contrast, cells bearing the KITD814V,
BCR-ABL, or FLT3N51 demonstrated constitutive phosphoryla-
tion of MLC (Figure 8A). H-1152 completely inhibited the consti-
tutive phosphorylation of MLC within 1 hr of treatment. These
results suggest that constitutive activation of ROCK and phos-
phorylation of MLC, which is inhibited by H-1152, might con-
tribute to the growth and survival of oncogene-bearing cells.
To investigate the role of MLC in MPD, we knocked downMLC
expression using shRNA in cells bearing KIT or KITD814V. Fig-
ure 8B shows significantly reduced expression of MLC in
shRNA-bearing cells compared to scrambled vector-bearing
cells. In addition, cells bearing KITD814V and shRNA showed
a significant reduction in constitutive growth compared to
cells bearing KITD814V and scrambled vector (Figure 8C).364 Cancer Cell 20, 357–369, September 13, 2011 ª2011 Elsevier Inc.Furthermore, mice transplanted with cells
coinfected with KITD814V and shRNA
survived significantly longer compared to
mice bearing cells coinfected with
KITD814V and scrambled vector (40–45
versus 26–34 days; *p < 0.05; Figure 8D).
Histopathological analysis of BM, spleen,
thymus, and lungs from transplanted
mice showed significantly increased infil-
tration of tumor cells in mice transplanted
with cells coinfected with KITD814V and
scrambled vector compared to KITD814V
and shRNA (Figure 8E). In contrast, micetransplanted with cells coinfected with KIT and scrambled vector
or shRNA did not die and showed no signs of MPD (data not
shown).These resultsdemonstrate invitroand invivo involvement
of MLC in KITD814V-induced MPD downstream from ROCK.
To further understand the mechanism behind cell death in
ROCK inhibitor-treated oncogene-bearing cells, we measured
F-actin content in 32D cells bearing KIT or KITD814V treated
with or without H-1152. Cells bearing KIT showed minimal
F-actin in the absence of growth factors (Figure S5D). In contrast,
cells bearing KITD814V showed constitutive F-actin in the
absence of growth factors that was repressed by H-1152 treat-
ment. Treatment of cells bearing KIT with H-1152 showed no
effect on F-actin content in the presence of IL-3. These results
suggest that inhibition of ROCK in KITD814V-bearing cells, but
not in normal cells, results in dephosphorylation of MLC, actin
filament destabilization, and disruption of cytoskeleton leading
to cell death. Similar findings were observed when these same
cells were treated with actin polymerization inhibitor cytocha-
lasin D (data not shown).
DISCUSSION
RhoA and its downstream target ROCK are frequently deregu-
lated in many human cancers. ROCK1 mutations have been
recently identified in human tumors that result in elevated
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Figure 7. Deficiency of ROCK1 Prolongs the
Survival of KITD814V-Bearing Mice
(A) HSC/PCs from WT and Rock1/ mice were
subjected to western blot analysis to confirm the
deletion of ROCK1.
(B) KITD814V-bearing HSC/PCs from WT or
Rock1/ mice were starved for 6 hr, cultured in
the presence and absence of IL-3 (10 ng/ml), SCF
(50 ng/ml), or GCSF (20 ng/ml) for 48 hr, then
proliferation was evaluated. Bars denote the mean
thymidine incorporation ± SD from one of five
independent experiments in quadruplicate (*p <
0.05, KIT versus KITD814V; **p < 0.05, KITD814V
versus Rock1/KITD814V).
(C) Kaplan-Meier survival curves of WT mice
transplanted with WT or Rock1/ cells bearing
KITD814V (n = 7; *p < 0.01).
(D–F) Reduced splenomegaly and hepatomegaly
in mice transplanted with Rock1/ cells bearing
KITD814V.Mean ±SD (n = 6–7; *p < 0.01). See also
Figure S4.
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ROCK in Myeloproliferative Diseasekinase activity and contribute to cancer progression (Lochhead
et al., 2010; Sahai and Marshall, 2002). Although data with
respect to the role of ROCK in solid tumors are slowly emerging,
the involvement of ROCK in AML and MPD remains unclear. We
provide in vitro and in vivo genetic, biochemical, as well as phar-
macologic evidence to suggest that ROCK plays an essential
role in regulating transformation via oncogenic forms of KIT,
FLT3, as well as BCR-ABL. Collectively, our results identify
PI3K/RhoA/ROCK/MLC pathway in regulating hematologic
malignancies via the activating mutations of KIT, FLT3, and
BCR-ABL.
With the success of imatinib for the treatment of CML, which
targets the Abelson kinase component of the BCR-ABL translo-
cation, a rational approach to less toxic and more efficacious
therapies for many hematologic malignancies including AML
and SM would likely involve targeting fundamental signaling
molecules bearing mutations in these diseases such as FLT3-
ITDs in AML and KIT mutations in SM and AML. Although KIT
mutations within the juxtamembrane region found in GISTs are
sensitive to inhibition by imatinib, KIT mutations within the tyro-
sine kinase domain in patients with AML and SM, such as
KITD814V, stabilize the KIT activation loop conformation in
its active form, which precludes sufficient imatinib binding forCancer Cell 20, 357–369, Setyrosine kinase inhibition (Demetri et al.,
2002; Frost et al., 2002; Ma et al., 2002).
Our results suggest that inhibition of
constitutively active ROCK in KITD814V-
bearing cells is a highly efficacious alter-
native approach for treating hematologic
malignancies involving KITD814V mu-
tation. In addition, inhibition of ROCK
in BCR-ABL-expressing cells results in
growth inhibition and apoptosis, which is
associated with dephosphorylation of
MLC. Furthermore, we show that inhibi-
tion of ROCK also results in growth sup-
pression of an imatinib-resistant BCR-
ABLT315I mutant.Although several cell type-specific mechanisms of ROCK acti-
vation have been described, how ROCK is activated in hemato-
poietic cells bearing oncogenic mutations such as KITD814V is
not known. In addition to protein oligomerization (Doran et al.,
2004), other direct activators of ROCK have been described
including intracellular second messengers such as arachidonic
acid and sphingosylphosphorylcholine that can activate ROCK
independently of Rho (Fu et al., 1998; Shirao et al., 2002).
Furthermore, ROCK1 activity can also be induced during
apoptosis. Cleavage of the carboxy-terminal autoinhibitory
region of ROCK1 has been reported by caspase 3. This type of
cleavage results in constitutively activated ROCK1 (Sebbagh
et al., 2001). Our results in KITD814V-bearing cells point to an
essential role for RhoA in regulating ROCK activation. We
show that treatment of KITD814V-expressing cells with C3
exoenzyme (a Rho inhibitor) not only inhibits ROCK activation
but also profoundly inhibits the growth of oncogene-bearing
cells. This observation is further confirmed using cells bearing
KITD814V and a dominant-negative version of Rho (RhoAN19).
Thus, RhoA is likely to regulate ROCK activity in KITD814V-
bearing cells by directly binding to the Rho-binding domain
(RBD) of ROCK. Binding of activated RhoA to the RBD is
thought to disrupt the negative regulatory interaction betweenptember 13, 2011 ª2011 Elsevier Inc. 365
A B
KITD814VKIT
pMLC MLC
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4
*C
250000
i
o
n
 
KIT
D
100
50000
100000
150000
200000
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
(
C
P
M
)
KITD814V
%
 
S
u
r
v
i
v
a
l
40
20
60
80 Vector shRNA
*
0
Vector
Vector
shRNA
T
h
y
Time (days)
0 10 20 30 40 50
0
FE
Oncogenes
KITD814V, BCR-ABL, 
FLT3 N51
PI3Kinase RhoA
shRNA
B
M
100μm 100μm
MYPT1 pMLC
Growth and Survival
S
p
l
e
e
n
h
y
m
u
s
100μm 100μm
MPD/AML
T
h
L
u
n
g
100μm
100μm
100μm
100μm
ROCK
Figure 8. MLC Contributes to the Growth of
Oncogene-Bearing Cells
(A) 32D cells bearing KIT, KITD814V, vector
(MIEG3), or BCR-ABL, and BaF3 cells bearing
FLT3 or FLT3N51 were starved for 6 hr, then
incubated in the presence or absence of H-1152
(2 mM) for 1 hr, and an equal amount of protein
lysates was subjected to western blot analysis.
Similar results were observed in three independent
experiments.
(B) 32D cells bearing KIT or KITD814V were co-
infected with vector or shRNA against MLC and
analyzed for MLC level by western blotting. Similar
results were obtained in two independent experi-
ments.
(C) Cells as in (B) were exposed to thymidine in-
corporation assay. Bars denote the mean thymi-
dine incorporation ± SD from one of three inde-
pendent experiments performed in quadruplicate
(*p < 0.01).
(D) Kaplan-Meier survival curves of mice trans-
planted with 1 3 106 cells described in (B) and (C)
(n = 6 in each group; *p < 0.01).
(E) Histopathological analysis of BM, spleen,
thymus, and lungs of mice in (D) by hematoxylin
and eosin staining. Shown are representative
tissue sections from various groups of trans-
planted mice.
(F) Model of ROCK activation in oncogene-bearing
cells. Oncogenes such as KITD814V, BCR-ABL, or
FLT3N51 induce constitutive activation of PI3K,
which further activates Rho GTPase, leading to
constitutive activation of ROCK. Activation of
ROCK causes phosphorylation of MLC and inac-
tivation of myosin phosphatase MYPT1 through
phosphorylation of myosin binding subunit (MBS).
Phosphorylation of MLC promotes cytoskeletal
contractility leading to cell growth and survival.
Inhibition of ROCK activity by inhibitors sup-
presses phosphorylation of MLC and causes
destabilization of actin filaments, thereby leading
to cell death. See also Figure S5.
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ROCK in Myeloproliferative Diseasethe catalytic domain and the C-terminal induced autoinhibition,
thereby activating ROCK. Upstream of RhoA, we provide strong
evidence to suggest that PI3K contributes to ROCK activation.
Utilizing a PI3K inhibitor, BM cells deficient in the expression of
p85a and a mutant form of KITD814V receptor that contains
only the binding site for p85a, our results show that p85a-
induced PI3K activity is essential for ROCK activation. It is likely
that PIP3 generated via the interaction between KITD814V and
p85a recruits and activates the GTPase exchange factor, which
in turn contributes to the activation of RhoA and subsequently
ROCK. Because PI3K pathway regulates multiple downstream
substrates as well as functions, our results suggest that perhaps
using ROCK inhibitors may be an alternative strategy for treating
hematologic malignancies in which ROCK is constitutively
activated.
Our preclinical studies, using a mouse model of KITD814V or
FLT3N51-driven MPD and treatment with H-1152 or fasudil,
suggest that inhibiting ROCK in vivo in oncogene-bearing cells
is of potential therapeutic significance. We show that H-1152
or fasudil-treatedmice show no signs of toxicity, which is consis-
tent with previous studies demonstrating lack of toxicity upon366 Cancer Cell 20, 357–369, September 13, 2011 ª2011 Elsevier InROCK inhibition in vivo using fasudil in human trials for cardio-
vascular indications (Shibuya et al., 2005). Based on these
observations, along with our genetic studies demonstrating
that constitutive growth of KITD814V-bearing cells in the setting
of ROCK1-deficient BM cells is normalized, targeting ROCK for
treatment of hematologic malignancies due to activating muta-
tions of KIT, FLT3, and BCR-ABL is likely to be a viable thera-
peutic option.
Activation of ROCKbyRho leads to phosphorylation of various
target proteins, including the LIM kinases as well as ERM.
Several other cytoskeletal-associated proteins have also been
described as ROCK substrates. In our studies we found MLC
to be constitutively hyperphosphorylated on Ser19 in all three
oncogene-bearing cells. Importantly, constitutive Ser19 phos-
phorylation of MLC was rapidly inhibited in the presence of
H-1152. Previous studies have shown that the organization of
cellular cytoskeleton is determined to a large extent by interac-
tions between actin and myosin (Elson, 1988) and that these
interactions are particularly crucial in cells undergoing rapid
growth and proliferation such as leukemic cells. The actin-
myosin interaction is largely regulated by the phosphorylationc.
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ROCK in Myeloproliferative Diseaseof MLC on Ser19 (Adelstein, 1983; de Lanerolle and Paul, 1991;
Somlyo and Somlyo, 1994). Although in smooth muscle cells
MLC phosphorylation and dephosphorylation are required for
muscle contraction and relaxation, our studies suggest that
dephosphorylation of MLC by H-1152 in leukemic cells is asso-
ciated with rapid F-actin depolymerization followed by mem-
brane blebbing and rapid cell death. Furthermore, we show
that this process is somewhat unique to oncogene-bearing cells.
These data suggest that unlike normal hematopoietic cells,
proliferation of oncogene-bearing cells such as KITD814V is
likely to be highly dependent on cytoskeleton deformation and
reformation, which is regulated by phosphorylation of MLC on
Ser19 by ROCK. Although our results suggest that MLC is clearly
involved in regulating aspects of MPD, ROCK has many addi-
tional targets that are also likely to contribute to MPD.
In conclusion our results suggest that KITD814V, FLT3N51,
and BCR-ABL induce constitutive activation of PI3K/Rho/
ROCK/MLC pathway, which increases actin-myosin responses
promoting cell growth and survival leading to MPD (Figure 8F).
Inhibition of ROCK using pharmacological inhibitors or sup-
pressing the expression ofMLC is sufficient to inhibit constitutive
growth of oncogene-bearing cells. ROCK1 appears to be suffi-
cient for inducing oncogene (at least for KITD814V)-mediated
transformation.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Rabbit anti-phospho-MYPT1 antibody was purchased from Upstate Biotech-
nology (Lake Placid, NY, USA). Rabbit anti-phospho-AKT, anti-AKT, anti-
phospho-ERK, anti-ERK, anti-phospho-Stat5, anti-Stat5, anti-phospho-PKC,
mouse anti-phospho-MLC, and anti-MLC antibodies were purchased from
Cell Signaling Technology (Beverly, MA, USA). Rabbit anti-ROCK1 antibody
was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Phycoerythrin (PE)-conjugated annexin V antibody and 7-amino actinomycin
D (7-AAD) were purchased from BD Biosciences PharMingen (San Jose, CA,
USA). ROCK inhibitors (fasudil and Y-27632) were purchased from Calbio-
chem (San Diego, CA, USA). Imatinib was purchased from Toronto Research
Chemicals Inc. (North York, Ontario, Canada). C3 exoenzyme was purchased
from Cytoskeleton Inc. (Denver). Recombinant murine and human IL-3, FLT3,
GM-CSF, SCF, IL-6, and Tpo were purchased from PeproTech (Rocky Hill, NJ,
USA). Retronectin was obtained from Takara (Madison, WI, USA). Iscove’s
modified Dulbecco’s medium (IMDM) was purchased from Invitrogen (Carls-
bad, CA, USA). Monothioglycerol was purchased from Sigma (St. Louis).
[3H]Thymidine was purchased from PerkinElmer (Boston). ROCK inhibitor
H-1152 was synthesized as described (US patent 6153600, November 28,
2000). Retroviral expression plasmids of dominant-negative mutant of RhoA
(RhoAN19) and Imatinib-resistant BCR-ABLT315I mutant were a gift from
Drs. Yi Zhang and Jose Cancelas, respectively, from Cincinnati Children’s
Hospital Medical Center, Cincinnati.
Mice
C57BL/6 mice and C3H/HeJ mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME, USA). p85a+/ and Rock1/mice have been previously
described (Terauchi et al., 1999;Vemulaet al., 2010b;Zhanget al., 2006). These
mice were maintained under specific pathogen-free conditions at the Indiana
University LaboratoryAnimalResearchCenter, Indianapolis, IN,USA.All animal
procedureswere conducted in accordancewith theGuidelines for theCare and
Use of Laboratory Animals and were approved by the Institutional Animal Care
and Use Committees (IACUCs) at Indiana University School of Medicine.
Patient Samples
Blast cells from the BM of patients with AML were obtained at the time of diag-
nostic testing after informed consent. Approval was obtained from the institu-Cantional review boards of Indiana University School of Medicine. The buoyant
fraction was isolated over Ficoll-Hypaque, and then washed with PBS before
processing as described previously (Hartman et al., 2006).
Cells
The murine IL-3-dependent myeloid cell line 32D cells bearing MIEG3 vector,
KIT, KITD814V, BCR-ABL, BCR-ABLT315I mutant, or RhoAN19 were cultured
in medium containing IMDM supplemented with 10% fetal bovine serum (FBS)
and murine IL-3 (10 ng/ml). The murine IL-3-dependent and G418-resistant
pro-B cell line BaF3-bearing FLT3 and FLT3N51 were obtained from Dr. Seiji
Fukuda (Shimane University, Izumo, Japan) and cultured in medium con-
taining IMDM supplemented with 10% FBS, G418 (2 mg/ml), and murine
IL-3 (5 ng/ml). The human mast cell leukemia line, bearing the KITV560G as
well as KITD816V mutations, HMC1.2 (Butterfield et al., 1988) and AML cell
line, bearing the FLT3-ITDmutation,MV4-11 (Lange et al., 1987) were obtained
from the American Type Culture Collection (Manassas, VA, USA) and cultured
in medium containing IMDM supplemented with 15% FBS and 1.2 mM
monothioglycerol.
Expression of WT and Oncogenic Receptors
Transduction of 32D and primary HSC/PCswas performed as described previ-
ously (Munugalavadla et al., 2007). After infection, 32D and primary HSC/PCs
bearing the WT or oncogenic receptors were sorted and used to perform all
experiments.
shRNA Silencing of MLC
The MLC-specific shRNA (CGCGCAACCTCCAATGTGTTCGCCATGTT) ex-
pression plasmid in retroviral vector pGFP-V-RSwas purchased fromOriGene
Technologies (Rockville, MD, USA). Purified and sequence-verified plasmid
containing a noneffective 29-mer sh eGFP cassette (scrambled vector) was
used as a negative control. Cells were transduced with scrambled vector or
shRNA plasmid as described above. After infection, cells were grown in the
presence of puromycin (10 ng/ml) to select the transduced cells.
Proliferation Assay
Proliferation was assessed by conducting a thymidine incorporation assay as
previously described (Munugalavadla et al., 2007).
Western Blotting
Western blotting was performed as previously described (Munugalavadla
et al., 2007).
Analysis of Cell Death
Cell death was assessed as previously described (Vemula et al., 2010a).
F-Actin Measurement
Cells were starved in serum- and cytokine-free media for 6 hr and cultured in
the presence or absence of IL-3 and H-1152 for 12 or 24 hr. After treatment,
cells were fixed with 4% paraformaldehyde in PBS for 15 min and washed
with PBS. After fixing, cells were quenched with 0.1 M glycine in PBS for
15min and washed with PBS. Then, cells were permeabilized with 0.2% Triton
X-100 (w/v) in PBS for 10 min and washed with PBS followed by blocking
nonspecific binding sites with 5% rat serum containing 0.2% BSA in PBS.
Cells were stained with FITC-conjugated phalloidin for 30 min, washed with
0.2% BSA in PBS, and analyzed by flow cytometry.
Mouse Leukemia Induction and In Vivo Drug Treatment
A total of 1 3 106 32D cells bearing KIT or KITD814V in 200 ml PBS were in-
jected into C3H/HeJ mice via tail vein. After 48 hr of transplantation, mice
were treated with vehicle (PBS) or H-1152 (66 mg/kg body weight) by oral
gavage at 12 hr interval for 14 days. In the second study mice were treated
with vehicle, H-1152 (50 mg/kg body weight, oral gavage), or fasudil
(25mg/kg body weight, intraperitoneal) at 24 hr intervals for 21 days. In a sepa-
rate study primary HSC/PCs bearing KITD814V were transplanted into syn-
genic C57BL/6 mice as previously described (Munugalavadla et al., 2008).
After 10 days of transplantation, mice were treated with vehicle, H-1152
(50 mg/kg body weight, oral gavage), or fasudil (25 mg/kg body weight, intra-
peritoneal) at 24 hr intervals for 21 days. In all studies mice were closelycer Cell 20, 357–369, September 13, 2011 ª2011 Elsevier Inc. 367
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ROCK in Myeloproliferative Diseasemonitored for MPD and harvested at moribund. BM, spleen, liver, and lungs
were fixed in 10% buffered formalin, and sections were stained with hematox-
ylin and eosin for histopathologic analysis.
Statistics
All graphical data were evaluated by paired Student’s t test, and results were
considered significantly different with a p value <0.05. All data are represented
as mean values ± standard deviations (SDs). Survival probability of trans-
planted mice groups was compared using a Kaplan-Meier survival analysis
in which statistical significance was determined as p values <0.05 by log
rank test.
SUPPLEMENTAL INFORMATION
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